Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide
0.1.0 - ci-build
Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide
0.1.0 - ci-build
Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide, published by Digital Health Agency (DHA), Kenya. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/IntelliSOFT-Consulting/nccpFHIRIG/ and changes regularly. See the Directory of published versions
| Active as of 2026-06-04 |
<CodeSystem xmlns="http://hl7.org/fhir">
<id value="med-clinical-category-cs"/>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: CodeSystem med-clinical-category-cs</b></p><a name="med-clinical-category-cs"> </a><a name="hcmed-clinical-category-cs"> </a><p>This case-sensitive code system <code>https://nshr-uat.sha.go.ke/fhir/CodeSystem/med-clinical-category-cs</code> defines the following codes:</p><table class="codes"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style="white-space:nowrap">CHEMOTHERAPY<a name="med-clinical-category-cs-CHEMOTHERAPY"> </a></td><td>Chemotherapy</td><td>Cytotoxic agent used to kill or inhibit cancer cells.</td></tr><tr><td style="white-space:nowrap">IMMUNOTHERAPY<a name="med-clinical-category-cs-IMMUNOTHERAPY"> </a></td><td>Immunotherapy</td><td>Agent that stimulates the immune system against cancer.</td></tr><tr><td style="white-space:nowrap">TARGETED-THERAPY<a name="med-clinical-category-cs-TARGETED-THERAPY"> </a></td><td>Targeted Therapy</td><td>Agent targeting specific molecular markers on cancer cells.</td></tr><tr><td style="white-space:nowrap">HORMONAL-THERAPY<a name="med-clinical-category-cs-HORMONAL-THERAPY"> </a></td><td>Hormonal Therapy</td><td>Agent that blocks or modifies hormone-driven tumour growth.</td></tr><tr><td style="white-space:nowrap">SUPPORTIVE-CARE<a name="med-clinical-category-cs-SUPPORTIVE-CARE"> </a></td><td>Supportive Care</td><td>Medication to manage side effects or improve tolerability.</td></tr><tr><td style="white-space:nowrap">ANTI-EMETIC<a name="med-clinical-category-cs-ANTI-EMETIC"> </a></td><td>Anti-emetic</td><td>Agent to prevent or treat nausea and vomiting.</td></tr><tr><td style="white-space:nowrap">GROWTH-FACTOR<a name="med-clinical-category-cs-GROWTH-FACTOR"> </a></td><td>Growth Factor</td><td>Colony-stimulating factor to support blood cell recovery.</td></tr><tr><td style="white-space:nowrap">CORTICOSTEROID<a name="med-clinical-category-cs-CORTICOSTEROID"> </a></td><td>Corticosteroid</td><td>Steroid given as part of or to support the oncology regimen.</td></tr><tr><td style="white-space:nowrap">BISPHOSPHONATE<a name="med-clinical-category-cs-BISPHOSPHONATE"> </a></td><td>Bisphosphonate</td><td>Agent for prevention or treatment of bone metastasis.</td></tr><tr><td style="white-space:nowrap">ANALGESIC<a name="med-clinical-category-cs-ANALGESIC"> </a></td><td>Analgesic</td><td>Pain management medication in the cancer care context.</td></tr></table></div>
</text>
<url
value="https://nshr-uat.sha.go.ke/fhir/CodeSystem/med-clinical-category-cs"/>
<version value="0.1.0"/>
<name value="MedClinicalCategoryCS"/>
<title value="Kenya Medication Clinical Category Code System"/>
<status value="active"/>
<experimental value="false"/>
<date value="2026-06-04T14:49:30+00:00"/>
<publisher value="Digital Health Agency (DHA), Kenya"/>
<contact>
<name value="Digital Health Agency (DHA), Kenya"/>
<telecom>
<system value="url"/>
<value value="https://dha.go.ke"/>
</telecom>
<telecom>
<system value="email"/>
<value value="info@dha.go.ke"/>
</telecom>
</contact>
<contact>
<name value="Digital Health Agency Kenya – FHIR Team"/>
<telecom>
<system value="email"/>
<value value="info@dha.go.ke"/>
<use value="work"/>
</telecom>
<telecom>
<system value="url"/>
<value value="https://dha.go.ke"/>
<use value="work"/>
</telecom>
</contact>
<description
value="Codes classifying the clinical role of a medication within an oncology regimen."/>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="KE"/>
<display value="Kenya"/>
</coding>
</jurisdiction>
<caseSensitive value="true"/>
<content value="complete"/>
<count value="10"/>
<concept>
<code value="CHEMOTHERAPY"/>
<display value="Chemotherapy"/>
<definition
value="Cytotoxic agent used to kill or inhibit cancer cells."/>
</concept>
<concept>
<code value="IMMUNOTHERAPY"/>
<display value="Immunotherapy"/>
<definition
value="Agent that stimulates the immune system against cancer."/>
</concept>
<concept>
<code value="TARGETED-THERAPY"/>
<display value="Targeted Therapy"/>
<definition
value="Agent targeting specific molecular markers on cancer cells."/>
</concept>
<concept>
<code value="HORMONAL-THERAPY"/>
<display value="Hormonal Therapy"/>
<definition
value="Agent that blocks or modifies hormone-driven tumour growth."/>
</concept>
<concept>
<code value="SUPPORTIVE-CARE"/>
<display value="Supportive Care"/>
<definition
value="Medication to manage side effects or improve tolerability."/>
</concept>
<concept>
<code value="ANTI-EMETIC"/>
<display value="Anti-emetic"/>
<definition value="Agent to prevent or treat nausea and vomiting."/>
</concept>
<concept>
<code value="GROWTH-FACTOR"/>
<display value="Growth Factor"/>
<definition
value="Colony-stimulating factor to support blood cell recovery."/>
</concept>
<concept>
<code value="CORTICOSTEROID"/>
<display value="Corticosteroid"/>
<definition
value="Steroid given as part of or to support the oncology regimen."/>
</concept>
<concept>
<code value="BISPHOSPHONATE"/>
<display value="Bisphosphonate"/>
<definition
value="Agent for prevention or treatment of bone metastasis."/>
</concept>
<concept>
<code value="ANALGESIC"/>
<display value="Analgesic"/>
<definition
value="Pain management medication in the cancer care context."/>
</concept>
</CodeSystem>